What the research found

Investigators across multiple academic medical centres analysed clinical records from over 9,000 patients who underwent mitral valve surgery for degenerative mitral regurgitation (DMR), alongside tissue samples and genetic data. They observed that patients taking SSRIs—drugs that reduce serotonin reuptake—required surgical intervention at a younger age than those not on these medications.

To explore whether this was biological rather than coincidental, researchers studied genetically modified mice lacking the serotonin transporter protein (SERT) and found their mitral valves thickened abnormally. Mice given high-dose SSRIs showed similar changes. In human valve tissue, researchers identified genetic variants in the SERT gene region that lowered transporter activity; cells carrying the "long-long" variant produced excess collagen and responded more strongly to serotonin exposure. These findings suggest that reduced SERT function may promote structural remodelling of valve tissue that's already degenerating.

Why it matters for you

If you're using SSRIs for mood or anxiety management, this research flags a potential consideration for long-term cardiovascular health monitoring—though the connection remains preliminary. The mechanism appears relevant specifically to DMR, a condition affecting millions but one most people won't develop. If you have a family history of valve disease or are being monitored echocardiographically, your clinician now has additional context for why SSRI-related valve changes might warrant closer surveillance rather than assumption of safety.

On a practical level: this isn't a signal to stop SSRIs if you need them. Rather, it underscores why baseline cardiac imaging and periodic follow-up imaging may be sensible for long-term SSRI users—especially as you age. If you're tracking biomarkers or optimising cardiovascular health, consider discussing echocardiography intervals with your doctor, particularly if you're on SSRIs and have other valve disease risk factors (age, hypertension, or genetic predisposition).

Caveats

• Observational data cannot prove causation: the clinical association between SSRI use and earlier surgery could reflect unmeasured confounding (e.g., depressed/anxious patients might have other health differences).
• Animal models at high doses: mice given very high SSRI doses and genetically null mice don't perfectly mirror human therapeutic exposure.
• Genetic variants are correlative: the "long-long" SERT variant associates with worse outcomes in DMR patients, but causality isn't established.
• **Mechanism shown in vitro only**: human valve cells in a dish don't capture whole-organism compensation or clinical disease progression.
• No data on stopping SSRIs: the research doesn't address whether dose reduction or cessation would alter valve trajectory.